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Abstract
French maritime pine bark extract (Pycnogenol®) displays a variety of anti-inflammatory effects in
vivo. Aim of this study was to determine whether human plasma after oral intake of Pycnogenol
contains sufficient concentrations of active principles to inhibit key mediators of inflammation.
Blood samples from seven healthy volunteers were obtained before and after five days
administration of 200 mg Pycnogenol per day. Plasma samples statistically significantly inhibited
matrix metalloproteinase 9 (MMP-9) release from human monocytes and NF-κB activation. Thus,
we provide evidence that bioavailable active principles of Pycnogenol exert anti-inflammatory
effects by inhibition of proinflammatory gene expression which is consistent with documented
clinical observations. We suggest that our ex vivo method is suitable to substantiate molecular
pharmacological mechanisms of complex plant extracts in a more focussed and rational way
compared to in vitro studies by taking into account the processes of absorption and metabolism.
Background
Pycnogenol is a standardized bark extract of the French
maritime pine Pinus pinaster (Pycnogenol®, Horphag
Research Ltd., UK). It comprises of a concentrate of pine
bark constituents such as polyphenolic monomers, procy-
anidins and phenolic or cinnamic acids and their glyco-
sides [1]. About 65–75 % of the Pycnogenol extract are
procyanidins that consist of catechin and epicatechin sub-
units of varying chain lengths [1]. The quality of this
extract is specified in the United States Pharmacopeia
(USP 28) [2].
In human studies Pycnogenol revealed diverse anti-
inflammatory actions [1]. Double-blind, placebo-control-
led studies in asthma patients showed reduced plasma [3]
or urine [4] leukotriene concentrations after Pycnogenol
supplementation, while asthma symptom scores and pul-
monary function improved. Symptoms of osteoarthritis
as pain and immobility of joints decreased in a double-
blind, placebo-controlled study [5]. Oral [6] and topical
[7] application of Pycnogenol reduced inflammation and
delayed skin-cancer formation following UV-radiation in
controlled experiments in mice.
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The anti-inflammatory mechanisms of maritime pine
bark extract have been elucidated in a variety of in vitro
and cell culture studies [8,9]. Additionally to its radical
scavenging activity an inhibition of NF-κB-dependent
gene expression and decrease of the activity of various
pro-inflammatory mediators and adhesion molecules was
observed after incubation of cells with the Pycnogenol
extract [8,9]. This experimental in vitro design that pursues
to uncover pharmacological effects by addition of plant
extracts to cell cultures and subsequent measurement of
cellular responses is widely employed. However, this
methodology might inherit a couple of pitfalls.
Plant extracts often comprise of high molecular weight
components that cannot be absorbed in the gastrointesti-
nal tract and thus will never reach a target cell in vivo. Fur-
thermore, there are examples of metabolites that are not
present in the original extract, but are formed in vivo as a
result of intestinal bacterial and/or hepatic metabolism.
After ingestion of Pycnogenol, for example, two metabo-
lites derived from catechin were detected in human urine,
δ-(3,4-dihydroxy-phenyl)-γ-valerolactone and δ-(3-meth-
oxy-4-hydroxy-phenyl)-γ-valerolactone [10]. Valerolac-
tone derivatives were also found after ingestion of green
tea [11]. These newly formed metabolites may display sig-
nificant efficacy and contribute to the observed in vivo
effects. We recently elucidated the cellular effects of δ-
(3,4-dihydroxy-phenyl)-γ-valerolactone and δ-(3-meth-
oxy-4-hydroxy-phenyl)-γ-valerolactone and uncovered an
antioxidant activity as well as the potential to inhibit
release and enzymatic activity of matrix metalloproteinase
9 (MMP-9) [12].
Thus, pharmacokinetic issues of absorption and metabo-
lism should be considered for valid identification of
molecular pharmacological effects of plant extracts. A
methodological approach that considers both the absorp-
tion and possible metabolism of plant extract compo-
nents would involve laboratory animals or human
volunteers who donate blood samples. These blood sam-
ples should contain all bioavailable active principles of
the extract and allow an ex vivo analysis in all kind of
molecular pharmacological effects in cell culture assays
(Figure 1). There are only few examples of experimental
settings described in literature that use this approach.
Effects of nettle herb [13] or willow bark extract [14] on
cytokine release and effect of Harpagophytum extract on
eicosanoid biosynthesis [15] were elucidated in whole-
Schematic representation of the experimental procedure of the ex vivo experiments with human plasma incubated with mono- cytes Figure 1
Schematic representation of the experimental procedure of the ex vivo experiments with human plasma incubated with mono-
cytes.
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blood assays of human volunteers after ingestion of the
extract. Recently, a potent ex vivo anti-HIV activity was
detected in sera of volunteers after administration of
Phyllanthus amarus plant material [16].
The purpose of the present study was to determine molec-
ular pharmacological effects of maritime pine bark extract
ex vivo after intake of regular doses by human volunteers.
Therefore, we obtained plasma samples before and after
five days administration of Pycnogenol to seven healthy
humans. These plasma samples were analyzed in two dif-
ferent experimental settings to evaluate the influence of
bioavailable actives principles on cellular key compo-
nents that contribute to inflammatory processes. We
investigated a potential influence of the plasma samples
on LPS-induced release of MMP-9 from human mono-
cytes. Since MMP-9 induction and release might be initi-
ated by NF-κB activation we also determined the effect of
the plasma samples on LPS-induced NF-κB nuclear trans-
location.
Methods
Patients
Seven healthy volunteers (five female and two male) aged
18 to 30 years participated in this study. The study was
approved by the ethical committee of the Comenius Uni-
versity's Faculty of Medicine, Bratislava, Slovak Republic,
and all participants gave written informed consent. After
24 hours of a diet free of flavonoids (no vegetables, fruits
and fruit juices or marmalades, tea, coffee, cocoa, wine
and beer) blood samples were drawn to obtain basal val-
ues. Subsequently, the volunteers took tablets containing
200 mg standardized maritime pine bark extract (Pycnog-
enol®, Horphag Research Ltd., UK) every morning for five
days to reach steady state conditions of constituents and/
or metabolites of Pycnogenol. Four hours after the last
intake of Pycnogenol on day five a second blood sample
was obtained from each volunteer. Again, a 24 hour
period of a diet free of flavonoids preceded this blood
sampling. Blood samples were centrifuged and plasma
was aliquoted, shock frozen and stored at -80°C until fur-
ther analysis.
Isolation and culture of human monocytes
Human monocytes were isolated from pooled blood cell
suspensions (Bayerisches Rotes Kreuz, Wiesentheid, Ger-
many) from different donors by Biocoll (Biochrom, Ber-
lin, Germany) and subsequent Percoll (Pharmacia,
Freiburg, Germany) density gradient centrifugation. Only
blood cell suspensions of donors with blood type 0 were
used for these experiments. The cells were first cultured
overnight in Mc Coy's 5a modified medium (Biochrom,
Berlin, Germany) supplemented with 15 % fetal calf
plasma, 1 % penicilline/streptomycine, 1 % non-essential
amino acids and 1 mM L-glutamine at a density of 5 × 106
cells/mL (NF-κB experiments) or 1 × 106 cells/mL (MMP-
9 experiments) in a 6 % CO2 humidified atmosphere at
37°C (Hera cell incubator, Kendro Laboratory Products,
Hanau, Germany). Cell experiments were performed in
Multiwell™ 24-well cell culture plates, polystyrene, (BD
Labware NJ, USA) with a final volume of 2.0 mL/well.
Inhibition of MMP-9 release from human monocytes
Plasma samples obtained before and after Pycnogenol
intake were diluted 1:1 with RPMI medium (Biochrom,
Berlin, Germany; supplemented with 1 % penicilline/
streptomycine, 1 % non-essential amino acids and 1 mM
L-glutamine) and incubated with monocytes for one
hour. Cells were then stimulated with 10 ng/ml LPS
(Lipopolysaccharides (rough strains) from Salmonella
minnesota Re 595, Sigma-Aldrich Inc., Taufkirchen, Ger-
many) and incubated at 37°C for 48 hours. The number
of viable cells was determined by counting living cells
after staining with trypane blue. Plates were centrifuged
(Megafuge 1.0 R, Kendro Laboratory Products) and cell
culture supernatants were harvested, diluted 1:25 and
assayed for total MMP-9 protein concentrations by ELISA
(Quantikine™ assay, R&D Systems, Minneapolis, USA)
according to manufacturer's protocol.
Determination of NF-κB activation by ELISA
Plasma samples obtained before and after Pycnogenol
intake were diluted 1:1 with RPMI medium as described
above and incubated with monocytes overnight. Cells
were then stimulated with 1 μg/mL LPS and incubated at
37°C for 60 minutes. After incubation the number of via-
ble cells was determined by counting living cells after
staining with trypane blue. Determination of free p65 in
nuclear extracts was performed according to the manufac-
turer's protocol (ELISA-Kit NF-κB p65 ActivELISA™,
Imgenex, CA, USA). The optical density of samples was
determined using the microplate reader (Bio-Rad micro-
plate reader, Benchmark CA, USA) set at 405 nm. Inhibi-
tory effects of plasma constituents and metabolites after
Pycnogenol intake were determined by comparing the
p65 concentration of LPS-stimulated cells, incubated with
plasma before and after Pycnogenol intake.
Statistical analysis
Statistical analysis (Wilcoxon matched pairs signed rank
test) was performed using the GraphPad prism software
(GraphPad Software Inc., San Diego CA, USA). Signifi-
cance was defined as p < 0.05.
Results
Human monocytes were incubated with diluted plasma
samples (dilution 1:1 with cell culture medium) obtained
from seven healthy volunteers before and after ingestion
of maritime pine bark extract (Figure 1). The viability of
monocytes was not significantly influenced by plasmaJournal of Inflammation 2006, 3:1 http://www.journal-inflammation.com/content/3/1/1
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samples obtained from Pycnogenol treated subjects. In
the MMP-9 experiments the number of viable monocytes
was 2.49 ± 0.23 × 105 after incubation with samples
obtained before Pycnogenol intake and 2.79 ± 0.26 × 105
after incubation with plasma obtained after 5 days Pyc-
nogenol ingestion. Likewise, no difference was observed
in the number of viable cells in the NF-κB experiments.
The number of viable monocytes was 1.49 ± 0.29 × 106
and 1.70 ± 0.20 × 106 after incubation with samples
obtained before and after 5 days Pycnogenol intake.
A statistically significant decrease of MMP-9 concentra-
tion in cell culture supernatant was induced by the plasma
samples obtained after intake of Pycnogenol compared to
basal values (Figure 2). The mean MMP-9 concentration
after LPS challenge of monocytes incubated with volun-
teers' plasma samples obtained before Pycnogenol inges-
tion was 17.06 ± 2.17 ng/mL per 2.5 × 105 viable human
monocytes. This concentration was reduced to 12.70 ±
1.24 ng/mL when monocytes were incubated with plasma
obtained after 5 days Pycnogenol intake. This corre-
sponded to a mean decrease in MMP-9 concentration of
25 %. The plasma of all study participants exhibited an
inhibitory effect on LPS-induced MMP-9 secretion, but
interindividual variations were obvious. The inhibitory
effect ranged from 4.6 % to 39 % inhibition.
A statistically significant reduction of nuclear p65 concen-
tration was observed when human monocytes were
exposed to plasma (dilution 1:1 with cell culture
medium) obtained after intake of Pycnogenol compared
to basal values (Figure 3). For this experiment, sufficient
volumes of plasma were only available from five volun-
teers; two plasma samples had been used up for repetition
experiments after cell culture contamination. The mean
nuclear p65 concentration after LPS challenge was 2.98 ±
0.48 ng per 1.5 × 106 viable human monocytes. This
nuclear concentration was reduced to 2.51 ± 0.26 ng per
Inhibition of LPS-induced matrix metalloproteinase 9 (MMP- 9) from human monocytes by plasma of seven volunteers  before and after five days intake of 200 mg maritime pine  bark extract (Pycnogenol) Figure 2
Inhibition of LPS-induced matrix metalloproteinase 9 (MMP-
9) from human monocytes by plasma of seven volunteers 
before and after five days intake of 200 mg maritime pine 
bark extract (Pycnogenol). The upper panel shows concen-
trations of MMP-9 in cell culture supernatants of 2.5 × 105 
viable cells after ex vivo incubation with the individual volun-
teers' plasma. The lower panel displays mean and standard 
deviation of percentage MMP-9 release. It statistically signifi-
cantly reduced by plasma samples after administration of Pyc-
nogenol (p < 0.01, Wilcoxon matched pairs signed rank test).
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Inhibition of LPS-induced NF-κB activation by plasma of five  volunteers before and after five days intake of 200 mg mari- time pine bark extract (Pycnogenol) Figure 3
Inhibition of LPS-induced NF-κB activation by plasma of five 
volunteers before and after five days intake of 200 mg mari-
time pine bark extract (Pycnogenol). The upper panel shows 
concentrations of p65 was determined in nuclear extracts of 
1.5 × 106 viable human monocytes after ex vivo incubation 
with the individual volunteers' plasma. The lower panel dis-
plays mean and standard deviation of percentage nuclear 
concentration of p65. It was statistically significantly reduced 
by plasma samples after administration of Pycnogenol (p < 
0.05, Wilcoxon matched pairs signed rank test).
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1.5 × 106 viable cells when monocytes were incubated
with plasma obtained after 5 days Pycnogenol intake. The
plasma of all study five participants exhibited an inhibi-
tory effect on LPS-induced NF-κB activation, but interin-
dividual variations were obvious. The inhibitory effect
ranged from 6 % to 25 % with a mean of 15.5 % inhibi-
tion.
For five volunteers whose plasma samples were used for
both the MMP-9 secretion and NF-κB experiments a cor-
relation of their plasmas' inhibitory activity on MMP-9
secretion and NF-κB nuclear translocation was calculated
(Figure 4). The correlation (Spearman rank correlation
coefficient) was positive (r = 0.6) though not statistically
significant due to limited number of samples.
Discussion
Plant extracts may display a variety of interesting pharma-
cological effects in vivo. The bioefficacy of plant extracts is
increasingly tested and documented in clinical interven-
tion studies [17]. While the efficacy of extracts is observed
with increasing interest the elucidation of the molecular
basis of biological or clinical effects remains a challenge.
Usually plant extracts comprise of a complex mixture of
various components and often enough it is not clear
whether a single compound or a mixture of related com-
pounds is responsible for the effects.
The standardized maritime pine bark extract Pycnogenol
has documented clinical anti-inflammatory activities
[1,9]. In earlier studies we determined that the extract's
metabolites  δ-(3,4-dihydroxy-phenyl)-γ-valerolactone
and  δ-(3-methoxy-4-hydroxy-phenyl)-γ-valerolactone
exhibited inhibitory activity on LPS-induced secretion of
matrix metalloproteinase 9 (MMP-9) from human mono-
cytes [12]. However, so far it remained elusive whether
sufficiently high in vivo concentrations of any active
extract components would be achieved after peroral
intake of Pycnogenol. In the present study we applied an
ex vivo methodology that takes absorption and metabo-
lism of the extract into account. The plasma samples
obtained from volunteers after ingestion of Pycnogenol
were expected to contain active extract components that
should attenuate inflammatory processes.
Indeed, we observed a statistically significant mean
decrease of about 25 % in MMP-9 release when LPS-acti-
vated human monocytes were exposed to plasma of vol-
unteers after repeated intake of Pycnogenol. The matrix
degrading enzyme MMP-9 is highly expressed at sites of
inflammation and contributes to the pathogenesis of var-
ious chronic inflammatory diseases. In asthma MMP-9 is
upregulated and involved in remodeling processes [18-
20]. MMP-9 also facilitates recruitment of inflammatory
cells such as eosinophils and neutrophils across basement
membranes [18]. Expression of MMP-9 was negatively
correlated with pulmonary function in asthmatic patients
[20]. As Pycnogenol has been reported to attenuate signs
of inflammation in asthma patients [3,4] we now provide
first evidence that this anti-inflammatory in vivo effect
might be at least partially attributed to reduced MMP-9
secretion on a molecular level.
NF-κB is a molecule with a master function in inflamma-
tory cytokine induction. It is also involved in regulation of
immune functions, cell cycle control and apoptosis [21].
Upon nuclear translocation in response to an inflamma-
tory stimulus it regulates various genes coding for proin-
flammatory mediators. We found that plasma of
Pycnogenol treated volunteers statistically significantly
inhibited NF-κB activation in LPS-stimulated monocytes
by about 15 %. Though this effect is rather moderate it
might well contribute to the anti-inflammatory effects of
Pycnogenol in patients. Interestingly, NF-κB is also
involved in MMP-9 expression [22,23]. Consistent with
these reports we observed a positive correlation between
inhibitory activity of matched plasma samples on MMP-9
and NF-κB. In vitro inhibition of NF-κB activation by plant
extracts or constituents has been reported repeatedly [24].
Blocking IκB kinase activity has been reported as the
underlying mechanism for restricting NF-κB activation by
green tea polyphenols [25]. The mechanism of ex vivo
inhibition of NF-κB nuclear translocation by plasma con-
taining bioavailable active principles after Pycnogenol
ingestion has yet to be identified.
To summarize, regular doses of perorally administered
French maritime pine bark extract moderately inhibited
NF-κB activation and MMP-9 secretion ex vivo. Since the
plasma samples of the volunteers were diluted 1:1 with
cell culture medium before incubation with the mono-
Correlation of inhibition of LPS-induced NF-κB activation  and MMP-9 release by matching plasma samples of five volun- teers before and after five days intake Figure 4
Correlation of inhibition of LPS-induced NF-κB activation 
and MMP-9 release by matching plasma samples of five volun-
teers before and after five days intake. Coefficient of correla-
tion was 0.6 (Spearman rank correlation coefficient).
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cytes it can be assumed that in vivo effects might be even
more pronounced. The observed ex vivo effects with
plasma of volunteers after Pycnogenol intake are consist-
ent with reported clinical anti-inflammatory effects in
vivo. The next challenge will be to identify the responsible
active principle(s) in the plasma samples. After all, how-
ever, the suggested methodology is a rational and
focussed technique to explain biological effects from in
vivo studies on a molecular pharmacological basis. The
next target will be to link pharmacodynamic data with
pharmacokinetics and to identify the active component(s)
in plasma samples.
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